These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 10615856)

  • 1. Metabolism-based anticancer drug design.
    Kwon CH
    Arch Pharm Res; 1999 Dec; 22(6):533-41. PubMed ID: 10615856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prodrugs in cancer chemotherapy.
    Connors TA; Knox RJ
    Stem Cells; 1995 Sep; 13(5):501-11. PubMed ID: 8528099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enzyme-catalyzed activation of anticancer prodrugs.
    Rooseboom M; Commandeur JN; Vermeulen NP
    Pharmacol Rev; 2004 Mar; 56(1):53-102. PubMed ID: 15001663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prodrugs for targeted tumor therapies: recent developments in ADEPT, GDEPT and PMT.
    Tietze LF; Schmuck K
    Curr Pharm Des; 2011; 17(32):3527-47. PubMed ID: 22074425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of prodrugs for enzyme-mediated, tumor-selective therapy.
    Yoon KJ; Potter PM; Danks MK
    Curr Med Chem Anticancer Agents; 2005 Mar; 5(2):107-13. PubMed ID: 15777218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates.
    Wallace PM; Senter PD
    Methods Find Exp Clin Pharmacol; 1994 Sep; 16(7):505-12. PubMed ID: 7885077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The choice of prodrugs for gene directed enzyme prodrug therapy of cancer.
    Connors TA
    Gene Ther; 1995 Dec; 2(10):702-9. PubMed ID: 8750009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer chemotherapy and drug metabolism.
    Riddick DS; Lee C; Ramji S; Chinje EC; Cowen RL; Williams KJ; Patterson AV; Stratford IJ; Morrow CS; Townsend AJ; Jounaidi Y; Chen CS; Su T; Lu H; Schwartz PS; Waxman DJ
    Drug Metab Dispos; 2005 Aug; 33(8):1083-96. PubMed ID: 16049130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumour prodrug development using cytochrome P450 (CYP) mediated activation.
    Patterson LH; McKeown SR; Robson T; Gallagher R; Raleigh SM; Orr S
    Anticancer Drug Des; 1999 Dec; 14(6):473-86. PubMed ID: 10834269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An improved synthesis of lysosomal activated mustard prodrug for tumor-specific activation and its cytotoxic evaluation.
    Adidala R; Devalapally H; Srivari C; Devarakonda R K; Akkinepally RR
    Drug Dev Ind Pharm; 2012 Sep; 38(9):1047-53. PubMed ID: 22185667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemically stable, lipophilic prodrugs of phosphoramide mustard as potential anticancer agents.
    Kwon CH; Moon KY; Baturay N; Shirota FN
    J Med Chem; 1991 Feb; 34(2):588-92. PubMed ID: 1995881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytochrome P450 gene-directed enzyme prodrug therapy (GDEPT) for cancer.
    Chen L; Waxman DJ
    Curr Pharm Des; 2002; 8(15):1405-16. PubMed ID: 12052216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toxicity mechanism-based prodrugs: glutathione-dependent bioactivation as a strategy for anticancer prodrug design.
    Zhang XY; Elfarra AA
    Expert Opin Drug Discov; 2018 Sep; 13(9):815-824. PubMed ID: 30101640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of oxazaphosphorines by cytochrome P450: application to gene-directed enzyme prodrug therapy for cancer.
    Roy P; Waxman DJ
    Toxicol In Vitro; 2006 Mar; 20(2):176-86. PubMed ID: 16293390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advances in small molecule prodrugs for cancer therapy.
    Wang P; Jin X; Cai J; Chen J; Ji M
    Anticancer Agents Med Chem; 2014 Mar; 14(3):418-39. PubMed ID: 23869777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nitro reduction as an electronic switch for bioreductive drug activation.
    Siim BG; Denny WA; Wilson WR
    Oncol Res; 1997; 9(6-7):357-69. PubMed ID: 9406242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An activatable prodrug for the treatment of metastatic tumors.
    Kim EJ; Bhuniya S; Lee H; Kim HM; Cheong C; Maiti S; Hong KS; Kim JS
    J Am Chem Soc; 2014 Oct; 136(39):13888-94. PubMed ID: 25238144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sensor/effector drug design with potential relevance to cancer.
    Fry FH; Jacob C
    Curr Pharm Des; 2006; 12(34):4479-99. PubMed ID: 17168755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nitroaryl phosphoramides as novel prodrugs for E. coli nitroreductase activation in enzyme prodrug therapy.
    Hu L; Yu C; Jiang Y; Han J; Li Z; Browne P; Race PR; Knox RJ; Searle PF; Hyde EI
    J Med Chem; 2003 Nov; 46(23):4818-21. PubMed ID: 14584930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypoxia-activated prodrugs in cancer therapy: progress to the clinic.
    Denny WA
    Future Oncol; 2010 Mar; 6(3):419-28. PubMed ID: 20222798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.